HSD17B14

Across TCGA pan-cancer cohorts, HSD17B14 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSD17B14 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher HSD17B14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSD17B14 expression acts as an unfavorable survival marker.

ESCA, STAD, and CHOL are the cancer types where HSD17B14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	All	0.075	0.533	<.001	12	view →
STAD	DFS	Median	All	0.211	0.709	.019	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSD17B14–ESCA (DFS)

Open the ESCA breakdown →